skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Biosimilars represent both vast opportunities and uncharted threats across pharma. The expert analysts at Pharma Intelligence continually monitor the emerging Biosimilars market with up-to-date analysis of global market access and trial strategies, information regarding biosimilars for autoimmune diseases, exclusive Physician and KOL insights, and cutting-edge ROI analysis. Strategically align yourself with the trajectory of Biosimilars for 2017, and effectively plan for a profitable future.

Stay ahead of the Biosimilars market with materials from Datamonitor Healthcare and Trialtrove, part of the Informa Pharma Intelligence suite of products. Whether you’re developing a strategy to defend profits against newly emerging Biosimilars, or seeking to accurately assess new opportunities in Biosimilars investment, we have the intelligence you need to accurately inform your business decisions.

Discover our content on biosimilars today

Uncover the market issues and trends affecting Biosimilars. The full report contains vital information for Biosimilars approved for the US market, and contains information like:

  • An overview of the Biosimilars market
  • Table: FDA Guidance on Biosimilars Published to Date
  • Substitution and naming policy controversies
  • Data and market exclusivity of biologics

Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years. This essential report covers:

  • The impacts of faster clinical development timelines promises
  • The global availability of the innovator drugs
  • Updates on current development programs
  • The challenges and successes of Biosimilars for autoimmune diseases

A snapshot view of aspects of the developing Biosimilar market, it covers information including:

  • Which companies faced the most biosimilar competition last year·
  • Leading companies for biosimilar launches, 2016
  • Number of biosimilars in active development by phase, 2011-2016
  • Biosimilar deal volume
  • Key biosimilar alliances by potential value

Case studies

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: